Oxytocin is a neurohypophyseal hormone that is produced centrally by neurons in the paraventricular nucleus and supraoptic nucleus of the hypothalamus. It is released directly into higher brain centres and into the peripheral circulation where it produces a multitude of effects. Classically, oxytocin is known for inducing uterine contractions at parturition and milk ejection during suckling. Oxytocin also acts in a species and gender specific manner as an important neuromodulator. It can affect behaviours associated with stress and anxiety, as well social behaviours including sexual and relationship behaviours, and maternal care. Additionally, oxytocin has been shown to have a variety of physiological roles in peripheral tissues, many of which appear to be modulated largely by locally produced oxytocin, dispelling the notion that oxytocin is a purely neurohypophyseal hormone. Oxytocin levels are altered in several diseases and the use of oxytocin or its antagonists have been identified as a possible clinical intervention in the treatment of mood disorders and pain conditions, some cancers, benign prostatic disease and osteoporosis. Indeed, oxytocin has already been successful in clinical trials to treat autism and schizophrenia. This review will report briefly on the known functions of oxytocin, it will discuss in depth the data from recent clinical trials and highlight future targets for oxytocinergic modulation.
Introduction
Oxytocin was named for its ability to induce uterine contractions (1) and was the first peptide to be synthesised in its biologically active form (2) . Oxytocin is mainly produced by the magnocellular neurons of the paraventricular (PVN) and supraoptic nuclei (SON) of the hypothalamus, and is released directly into higher brain regions or into the blood stream via projections that extend to the neurohypophysis (1) . In the rat, oxytocin neurons are known to project into the central, anterior, basal and lateral amygdala, substantia nigra, nucleus tractus solitaris, nucleus motoris dorsalis vagus, nucleus reticularis lateralis and into the spinal cord (3) . Within the medulla, PVN neurons project to the dorsal motor nucleus of the vagus, commissural nucleus and the lateral reticular nucleus (3) . More recently, oxytocin synthesis has been observed in several tissues (1), e.g., the atria of the heart (4), prostate gland (5) and epididymis (6) .
Oxytocin is a nonapeptide that is structurally and functionally related to vasopressin and, owing to a high degree of contiguity, both peptides share partially overlapping functions and define larger classes of neurohypophyseal peptides that share a high degree of homology (1) . Classification into either vasopressin or oxytocin class of hormones is dependent on the amino acid present at position 8, with a neutral amino acid defining oxytocin class and a basic amino acid defining vasopressin class (1) .
The oxytocin gene is highly conserved between species and shares a common locus with the vasopressin gene. Oxytocin lies on the positive strand, whereas vasopressin lies on the negative strand. Hence, transcription of both genes occurs in opposite directions (7) . In humans, oxytocin is transcribed from a single copy gene on chromosome 20p13 comprising three exons and four interposing introns (7) ( Figure  1A ). The resulting translated 12.8-kDa nonapeptide forms a disulphide bridge between cysteine residues resulting in a six amino acid cyclic peptide with a three amino acid carboxyl tail (2) ( Figure 1B) .
The physiological regulation of the oxytocin gene remains elusive. There is evidence for tissue specific endocrine regulation as the OXTR promoter contains binding sequences for oestrogen (8) , retinoic acid (9) and thyroid hormone receptors (10) that overlap in a region referred to as a multihormone response element. Oxytocin is upregulated by oestrogen in the PVN and the uterus (11) . Oestrogen induced upregulation of uterine oxytocin is blocked by progesterone, whereas in the PVN it is blocked by the thyroid hormone (11, 12) .
Oxytocin exerts its biological effects by binding and activating the oxytocin receptor. The oxytocin receptor is a typical G-protein-coupled receptor containing seven transmembrane domains and is transcribed from a single copy gene on chromosome 3p25 in humans (13) . The receptor is widely expressed in mammalian organs including the brain, heart, epididymis, prostate, testis, uterus (1) and bone reflecting the pleotropic effects of oxytocin. The oxytocin receptor is unique in its ability to be rapidly upregulated and downregulated in response to stimuli including parturition (13) and, similar to the oxytocin gene, is under the transcriptional control of oestrogen (14) .
Activation of the oxytocin receptor results in several responses which are G protein and cell type dependent. Cou- (A) The oxytocin gene comprises three exons (numbered boxes) and four introns (line). The composite hormone response element (CHRE) and other conserved regions of hormone responsiveness are given with relative positions of promoter elements upstream (-) and downstream (q) of the transcript start site. Retinoic acid response elements (RARs) and thyroid hormone response elements (THREs) are shown, as is the full oestrogen response element (ERE) spanning the CHRE. Additional TGACC elements at -103 and -83 are able to produce a small oestrogen-mediated induction of the oxytocin promoter but these elements do not act synergistically with the ERE. The mRNA transcript is given identifying those exonic regions that encode the secretory signal peptide, oxytocin and oxytocin associated neurophysin (Np1) interspaced with a tripeptide linker. (B) Primary protein structure gives the amino acid number relative to the first cysteine. Cyclisation of the first six amino acids occurs through disulphide bond formation (s-s) between cysteines 1 and 6. Coupling of the oxytocin receptor to Ga q/11 activates a signalling cascade via phospholipase C-b (PLCb), phosphatidylinositol-4,5-bisphosphate (PIP2). This leads to the generation of diacylglycerol (DAG) and IP3. IP3 induces release of calcium from the endoplasmic reticulum (ER) and activation of the calcium calmodulin system. This results in smooth muscle contraction or neurotransmitter release in neurons. DAG causes activation of protein kinase C (PKC) and induces the MAP-kinase pathway resulting in phosphorylation of downstream targets such as ERK1/2. pling of the oxytocin receptor to Ga q/11 initiates a phospholipase C (PLC) dependent mechanism which induces the release of calcium from intracellular stores. Increased intracellular calcium can alter neuronal excitability and trigger neurotransmitter release in neurons or cause smooth muscle contraction (1) (Figure 2 ). In addition to the calcium dependent pathway, the oxytocin receptor can stimulate calcium independent pathways including RhoA and ERK dependent pathways. RhoA/Rho-kinase is activated by oxytocin resulting in phosphorylation of myosin-binding subunit of myosin phosphatase and contraction of uterine smooth muscle cells (15) . RhoA signalling is thought to be an important contributor to smooth muscle cell contraction as RhoA is markedly raised during pregnancy (15) . Additionally, oxytocin signalling can induce phosphorylation of ERK1/2 and ERK5 which can alter gene transcription and induce contraction in smooth muscle cells by increasing prostaglandin synthesis (16, 17) .
Classical actions of oxytocin
Oxytocin was first recognised for its roles in female physiology including the induction of labour and milk ejection, roles that are evidenced by increasing oxytocin levels during lactation and labour (18) . Additionally, oxytocin is the strongest uterogenic substance known to man and its agonists and antagonists have been used clinically to induce labour or halt premature labour, respectively (1) .
During parturition, circulating oxytocin levels rise dramatically owing to increased secretion from oxytocin neurons. Increased secretion from oxytocin neurons is engendered by a reduction in progesterone which causes activation of SON neurons (19) and is augmented by cervical and uterine stimulation (1, 20) . Moreover, the uterus becomes more sensitive to oxytocin with a rapid increase in oxytocin receptor expression that is induced by oestrogen (14) . Oestrogen induced oxytocin receptor upregulation can only occur following a reduction in progesterone secretion (14) . However, the role of oxytocin in parturition has been questioned as oxytocin null mice undergo parturition normally (21) . The administration of oxytocin antagonists during labour in mice have demonstrated that, although oxytocin does not induce labour, oxytocin affects labour progression and the timing of birth of pups subsequent to the first (22) . Its role in birthing of subsequent pups is highlighted by the heightened levels of oxytocin that are seen following the birth of the first pup (22) . The lack of major effects seen in the oxytocin null mouse model could be owing to compensation by vasopressin and other stimuli that increase prostaglandin synthesis, a final event in oxytocin-induced contraction of uterine smooth muscle (20) .
Oxytocin is secreted in response to suckling as part of a reflex. Suckling stimulates tactile receptors in the nipple which sends signals via the spinal cord into the PVN of the hypothalamus. Oxytocin is released in a pulsatile manner and induces contraction of the myoepithelial cells surrounding alveoli of the secretory lobes and surrounding the lactiferous ducts, promoting milk ejection (1) . Oxytocin deficient mice have illustrated the importance of oxytocin in the milk ejection reflex with pups dying soon after birth due to malnourishment despite normal maternal and suckling behaviours and milk production (21) .
Non-classical actions of oxytocins

Social behaviour
The relationship of oxytocin to social behaviour has been most frequently studied in the genus Microtus (voles) which show marked variations in social structure. Prairie voles form long-term monogamous relationships and are constantly observed to associate with their mates, produce a larger number of ultrasonic calls and secrete glucocorticoids in response to social isolation (23) . Alternatively, montane voles live in isolated burrows and show little affiliation, except following parturition (23) . Oxytocin receptor distribution in the brains of both species are different, presumably reflecting differences in social organisation. Prairie voles display the highest oxytocin receptor density in the prelimbic cortex, bed nucleus of stria terminalis, nucleus accumbens, midline nuclei of thalamus and lateral aspects of the amygdala. Conversely, the highest oxytocin receptor density in the montane vole is in the lateral septum, ventromedial nucleus of the hypothalamus and cortical nucleus of the amygdala (23) . A similar pattern is found in singing mice sp. that show differences in social affiliation (24) . The roles of oxytocin in social behaviour are supported by the observations that follow chronic administration of oxytocin, rats spend an increased amount of time engaging in non-sexual social behaviours such as sniffing and grooming (25) . Furthermore, in oxytocin null mice pervasive social deficits are observed such as a reduction in vocalisations following removal from the nest and increased aggression (26) . It is worth noting here that increased vocalisation of an unusual pattern has been reported in a mouse model of autism (27) , a social disorder in which oxytocin is implicated (see below).
Such evidence from animal studies identified oxytocin as a potential treatment for social dysfunction arising from autism, schizophrenia and mood disorders. Within the past 10 years, the effect of oxytocin on affiliative behaviour in humans has been investigated in clinical trials (Table 1) , the results of which are suggestive of oxytocin modulating social attachment. Oxytocin administration has been found to induce prosocial behaviours such as trust (28, 29) and can increase eye gazing, a behaviour that is necessary for identifying subtle social cues (30) . Indeed, in a double-blind randomised control study in young healthy males, intranasal oxytocin could improve their ability to recognise the mood of people in the ''seeing the eyes in the mind test'' where people were asked to assign a mood based on a photograph of only a subject's eyes (31) . Oxytocin has also been found to be important in regulating social memory in humans and can improve the ability of people to identify unfamiliar others from a single sighting (32) . Additionally, oxytocin administration can compensate for a lack of social contact and contribute towards general health and well-being (32) . Oxytocin has also been shown to improve positive communication during couple conflict (33) .
Sexual behaviour
In both males and females, oxytocin is important in inducing sexual behaviour, arousal and orgasm. All behaviours are centrally mediated in a region-dependent manner.
In male rats, oxytocin injected into the hippocampus can elicit erection (34) . The ability of oxytocin to induce erection is abolished by nitric oxide (NO) synthase inhibitors suggesting that oxytocin activates NO-synthase activity in the hippocampus (35) . NO in turn activates glutaminergic neurotransmission (35) . Inhibition of oxytocin with oxytocin antagonists reduced the number of mounts and intromissions in male rats, implicating a role for oxytocin in inducing male sexual behaviour (36) .
In female rats, oxytocin can induce behaviours indicative of sexual receptivity such as increased quotient and duration of lordosis when infused into the ventromedial hypothalamus (VMH) and the medial preoptic area (MPO) (37) . Administration to either area is dependent on steroid priming. Progesterone pretreatment is necessary for the induction of sexual behaviours in the VMH, whereas oestrogen priming is necessary for behaviour induction within the MPO (37) .
In humans, higher levels of oxytocin are associated with increased arousal and sexual response as well as heightened catecholamine release during arousal (38) . Oxytocin levels increase during intercourse and self-stimulation, and peak at orgasm in both sexes (39, 40) and is hypothesised to be important in inducing orgasm and sexual satiety (40). The effects of oxytocin on complex social cognition in adults NS with autism spectrum disorders NCT00263796
To study the effect of oxytocin on face processing and response NS inhibition in autistic adults by functional magnetic resonance imaging NCT01093768
To assess the effects of oxytocin and vasopressin on brain activity in NS healthy adult volunteers and adults with ASD using functional magnetic resonance imaging Schizophrenia NCT00506909 To determine if intranasal oxytocin can augment the effects of NS antipsychotic medication in subjects who still suffer symptoms NCT01028677
To test whether intranasal oxytocin improves social cognition, social NS functioning and decreases paranoia and other psychotic symptoms in schizophrenic subjects NCT01123317
To determine if intranasal oxytocin changes regional brain blood flow NS to better understand the role of oxytocin in the modulation of social judgement NCT00663039
To determine the efficacy of oxytocin nasal spray on social affiliation NS in schizophrenic patients NCT00884897
To determine if oxytocin enhances emotional intelligence and improves II performance on measures of social cognition in schizophrenic subjects NCT00813436
To identify the effect of intranasal oxytocin on empathic abilities in II people with schizophrenia NCT00789022
To determine oxytocin levels in the plasma of patients before and NS after neuroleptic treatment following their first psychotic episode Anxiety NCT00989937 To determine the efficacy of intranasal oxytocin to improve anxiety NS symptoms in a variety of anxiety disorders NCT00975416
To determine whether intranasal oxytocin as an adjuvant to cognitive IV behavioural therapy for drug dependence alters treatment outcome NCT01081249
To determine the effects of oxytocin on nonverbal behaviour NS in a psychotherapy session Pain NCT00963040 To investigate the efficacy of intranasal oxytocin to reduce headache NS symptoms (nausea, vomiting, photophobia, phonophobia) in chronic headache NCT00919802
To investigate the efficacy of intranasal oxytocin to reduce pain NS associated with interstitial cystitis NS, not specified.
Pair bonding
As with social affiliation, pair bonding has been most frequently studied in voles, particularly in prairie voles which display lifelong partner preference in response to mating and are monogamous (41) . In female prairie voles, mating is associated with an increase in central oxytocin. This is thought to be a sufficient stimulus for the development as partner preference because it can be elicited in virgin females following oxytocin infusions into the left lateral ventricle. Furthermore, this effect is blocked by the administration of oxytocin receptor antagonists prior to mating (41) . The development of partner preference is most probably as a result of an interaction between oxytocin receptors and dopamine receptors in the nucleus accumbens because blockade of either dopamine or oxytocin results in reduced partner preference (42) .
Maternal behaviour
Oxytocin signalling in the brain is thought to be responsible for the development and strength of interactions between females and their offspring in mammals who display prolonged periods of maternal care. In female rats, intracerebroventricular injection of oxytocin can induce maternal behaviours such as licking, crouching and grouping of pups (43) . These behaviours are partially dependent on the stage of the oestrous cycle that oxytocin administration occurs at, with the strongest induction of behaviours occurring in late dioestrous (43) . In ewes, an increase in oxytocin levels following vaginocervical stimulation is associated with the onset of maternal behaviour (44) . Increased central oxytocin levels are able to reduce aggression and foster the adoption of foreign lambs. These behaviours are dependent on oestrogen priming (44) .
Virgin rats (45) and prairie voles (46) display a differential maternal response when exposed to pups. The range of responses varies from full adoption to rejection of pups. In both species, the oxytocin receptor content in the amygdala is higher in animals that foster young compared to those that exhibit aggressive behaviours (45, 46) . In the polygamous montane vole, the onset of maternal behaviour is preceded by a redistribution of the oxytocin receptor in the brain (23) . The importance of oxytocin in maternal behaviour has been highlighted by CD38 null mice. CD38 activation is thought to induce Ca 2q -mediated oxytocin release (44) . Indeed, CD38
-/-exhibit reduced amounts of plasma and cerebrospinal fluid (CSF) oxytocin and display blunted maternal behaviours that are rescued by oxytocin administration (47) . These observations reflect those of oxytocin receptor knockout mice (26) .
Stress
The anxiolytic effect of oxytocin has been examined most recently in oxytocin null mice (45) . Anxiety behaviour, as measured using an open maze test, is increased in oxytocin null mice (48) . Administration of oxytocin depresses this effect (48) . The anxiolytic effects of oxytocin are mediated by altered cortisol and neurotransmitter release. Following acute stressors, such as isolation in a metabolic cage and rectal probing, female oxytocin null mice exhibit higher cortisol secretion compared with wild-type mice (49) . Additionally, female oxytocin null mice exhibit increased mean arterial pressure compared with wild-type mice following chronic shaker stress (50) . Altered pressor secretion is also noted but differs from that seen in acute stress, with a reduction in corticosterone release following chronic stress (50) . Oxytocin has also been shown to exert anxiolytic effects by activation of oxytocin receptors of serotonergic neurons of the raphe nucleus and subsequent serotonin release (51) .
In humans, intranasal oxytocin can induce a sense of calmness during a psychosocial stress test (52) and can reduce stress during couple conflict (33) . In both studies, oxytocin administration was associated with a reduction in cortisol secretion (33, 52) .
Cardiovascular functions
Oxytocin can reduce the blood pressure in isolated perfused hearts from cats, rabbits and chickens (53) . The response of rabbit hearts is variable. Some show no response to oxytocin. Of those that do respond marked differences in the time course of action and magnitude are observed (53) . The reduction is accounted for by decreased cardiac contractility and vasodilation. The ability of oxytocin to induce vasodilation (54) and reduce cardiac contractility (55) has been further illustrated in intact dogs. The fact that an effect is apparent in isolated hearts suggests that oxytocin can act locally. Indeed, oxytocin and its receptor are expressed within the heart (4, 56) and activation atrial oxytocin receptors are responsible for inducing atrial natriuretic peptide release that could explain the reduction in heart rate and contractility (56).
Oxytocin can also mediate blood pressure and heart rate responses centrally. Oxytocin neurons of the PVN are known to project into the vagal nerve and other cardiovascular centres in the brain (3). Oxytocin can increase vagal outflow to the heart accounting for the reduction in cardiac inotropy and chronotropy observed (57) .
In spontaneously hypertensive rats, oxytocin levels are reduced in the PVN whereas dorsal brain stem oxytocin receptor expression is reduced following the onset of hypertension (58) . The subsequent reduction in oxytocin responsiveness is hypothesised to mediate raised blood pressure. This is supported by the reduction in blood pressure following oxytocin treatment of spontaneously hypertensive rats (59) . Moreover, chronic exercise results in an increase in PVN and dorsal brain stem oxytocin concentrations concomitant with a reduction in basal blood pressure (60) . Similarly, exercise induces a rapid increase in oxytocin in the nucleus tractus solitarii. This effect blunts the tachycardic response to exercise as pretreatment with oxytocin antagonist prior to exercise potentiates the tachycardic response (61) . Oxytocin null mice exhibit altered cardiovascular functions with a decrease in mean arterial pressure and reduced heart rate (50).
Functions in the male reproductive tract
Oxytocin and its receptor are expressed in the penis, testis, epididymis and sex accessory glands of many species (62) . This is suggestive of a local oxytocinergic system operating in the male reproductive tract. Important roles for oxytocin in the testes have been proposed. First, it has been shown to affect steroidogenesis (63) (64) (65) . Second, oxytocin can promote the arrival of sperm in the epididymis by inducing seminiferous tubule contraction in a dose-dependent (66) and spermatogenic stage-dependent (67) manner that promotes shedding of spermatozoa from the seminiferous epithelium (spermiation) (68) . Spermiation is delayed in oxytocin null mice but is accelerated in mice overexpressing oxytocin (68) . Similarly, the arrival of sperm in the epididymis can also be increased by oxytocin in the rat by increasing tubular transport and spermiation (69) . Oxytocin also increases sperm movement through the epididymis by increasing spontaneous contractile activity (70) . Circulating levels of oxytocin increase significantly during sexual arousal (39) and promote contractility of erectile tissues of the penis (71). Furthermore, oxytocin levels peak at orgasm (39, 72) and are thought to contribute to ejaculation by inducing intense contractions of pelvic muscles (72) .
Targets for oxytocinergic signalling intervention
Oxytocin and its antagonist atosiban have been used clinically to manage labour for several years (73) . Atosiban is the only antagonist approved for the pharmacological prevention of preterm delivery. It should be noted that this antagonist has a higher affinity to the vasopressin V1a receptor and displays greater antagonism than of the oxytocin receptor, suggesting an important role of V1a in human par- (76) . Furthermore, some conditions can be contraindicated for the use of oxytocin therapy, such as benign prostatic hyperplasia and some cancers (reviewed below). Some clinical trials currently underway are outlined in Table 1 , whereas outcomes of some trials and proposed pathologies for oxytocinergic-targeted therapies are summarised in Table 2 .
Autism spectrum disorders
Autism spectrum disorders (ASDs) are marked by dysfunctional communication, repetitive motions and limited interests. Autistic subjects also display reduced eye gaze that results in an inability to identify subtle social cues such as emotions. Defects in the oxytocin signalling system, including reduced plasma oxytocin levels (77), have been identified in subjects with ASDs and are thought to contribute to social aspects of the disease. Reduced plasma oxytocin levels can result from single nucleotide polymorphisms of the CD38 gene (78) . Additionally, novel genetic polymorphisms in the oxytocin receptor gene, hypothesised to result in reduced affinity of oxytocin binding, have been identified in subjects with ASDs (79), as have decreased oxytocin receptor expression as a result of epigenetic silencing (80) . The use of oxytocin to treat ASDs in clinical trials has produced promising results. Following intravenous injection of oxytocin, subjects show a significant reduction in the frequency and number of different repetitive behaviours. This effect was increased with time (75) . Intranasal administration of oxytocin in ASD subjects results in improved performance in the 'seeing the mind in the eyes test' (81) where subjects are asked to assign emotions based on a photograph of a person's eyes (81) . Additionally, intravenous oxytocin infusions have been associated with an increased capacity to infer the moods of others from their speech (affective speech comprehension) (74) . These are the first reports of any pharmacological intervention that can acutely improve the social symptoms of autism.
Schizophrenia
Schizophrenia is marked with social detachment, memory defects and psychosis. Blood oxytocin is reduced in subjects with the disease, which can account for the social symptoms observed (82) . Treatment with neuroleptics and antipsychotics is known to increase the activity of neurons in the PVN and SON and could, therefore, be responsible for increasing oxytocin levels and alleviating some of the observed symptoms (83) . Despite this, patients often suffer from social and memory deficits and this has implicated oxytocin as an adjuvant treatment to antipsychotics. In addition to improving social functions, oxytocin can be important in reducing psychotic symptoms. Oxytocin null mice display increased susceptibility to psychosis induced by phencyclidine owing to altered glutamatergic functioning (84) . A clinical trial using oxytocin as an adjunct therapy to antipsychotics in schizophrenia patients has indicated that oxytocin can be beneficial in treating aspects of the disease (85) . Other trials are currently underway (Table 1) .
Mood and anxiety disorders
Depression is a common disorder marked by a reduction in social functioning, sexual dysfunction, disinterest in activities, disturbances to sleep patterns, eating patterns and cognitive dysfunction. In addition to psychosocial symptoms, people with depression often experience physical symptoms such as fatigue and generalised body aches. Antidepressants act to increase serotonin secretion and activity. Side effects of antidepressants include fatigue, increased appetite, weight gain, sweating and dry mouth. Some of these symptoms could potentially be due to inhibition of oxytocin release. Therefore, oxytocin could be used as an adjuvant to alleviate these side effects. Indeed, oxytocin could be a potential candidate to replace the use of antidepressants. In animal models of depression, administration of oxytocin (86) and oxytocin agonists (87) can induce an antidepressive effect as indicated by a reduction in learned helplessness and behavioural despair. The ability of oxytocin to induce antidepressive effects potentially arises from the fact that oxytocin can be activated by antidepressant therapy and can potentiate some of its effects (88) . In humans, however, the situation is somewhat more complicated. Oxytocin levels have been reported to be increased (89) or decreased (90) in depression, whereas chronic activation of the oxytocinergic system is indicated by an increase in the density of oxytocin neurons in the PVN (91) . Moreover, depressed patients show dysregulated oxytocin responses in laboratory sessions with a significant increase in oxytocin secretion in an imagery session (92) . Furthermore, in humans, oxytocin secretion appears to be unaffected by antidepressant therapy (89) . Oxytocin has also been identified as a potential agent to treat anxiety disorders such as social phobia and OCD. Indeed, oxytocin is known to have anxiolytic effects that are mediated by oxytocin induced release of serotonin in the raphe nucleus (50) . In a case study in the 1980s a hospitalised subject suffering from worsening OCD and who was not responsive to behavioural or drug therapies had reduced OCD symptoms following treatment (76) . Oxytocin administration in social phobia patients undergoing exposure therapy was able to improve outcomes (93) .
Cancer
The oxytocin receptor is expressed in a large number of tumours and tumour cell lines including those derived from lung (94), breast (95) , prostate (96) , endometrium (97) and ovary (98) . Oxytocin is known to be able to bind and activate functional receptors in these tumours altering cell proliferation and migration.
Proliferation
Oxytocin treatment can increase proliferation of small cell lung carcinoma lines (94) and choriocarcinoma cells (99) . By contrast, oxytocin inhibits cellular proliferation of breast (95) , ovarian (98) and endometrial carcinoma cells (97) . The reduction in proliferation in ovarian cancer cells has been illustrated in vivo following the injection of cells into the peritoneum of athymic nude mice (98) . Prostate cancer cell lines show differential responses to oxytocin. DU145 prostate cancer cells are inhibited by oxytocin treatment, PC3 prostate cancer cells are stimulated by oxytocin treatment, whereas LNCaP cells are unaffected by oxytocin treatment (96) .
The difference in proliferative effect of oxytocin appears to be due to ''G protein promiscuity''. That is, coupling of the oxytocin receptor to different G proteins is dependent on cell type and the localisation of the oxytocin receptor within the plasma membrane (100). In HEK293 when the oxytocin receptor was targeted to caveolin enriched domains, coupling to Ga q resulted in a transient ERK1/2 phosphorylation that stimulated cellular proliferation (101) . Alternatively, when the oxytocin receptor is located outside of caveolar microdomains, it is coupled to Ga i , ERK phosphorylation appears to be sustained with an antiproliferative effect observed (101) (Figure 3) . The proliferative effects can thus be altered by depleting the membrane of cholesterol or by targeting the oxytocin to caveolae (102, 103) . Recent studies suggest that this situation is reversed in prostate cancer. Oxytocin-stimulated PC3 prostate cancer cells do not form caveolae because they lack the caveolae-essential protein, PTRF (104) . By contrast, oxytocin-inhibited DU145 cells do form caveolae, and dispersal of caveolae with cyclodextrin reverses this antiproliferative effect (96) . However, it is necessary to note that cyclodextrin removes cholesterol from the membrane and cholesterol is necessary for the proper functioning of G-protein-coupled receptors (1).
Migration
In some tumour cell types, the effect of oxytocin on migration and invasion has been investigated. In PC3 cells, oxytocin stimulates migration. This is owing to a combined effect of EGFR transactivation and ERK1/2 phosphorylation initiated by signalling through Ga i (105) . In ovarian SKOV3 cells, oxytocin treatment reduces migration and invasion in vitro. This is associated with a reduction in matrix metalloproteinase-2 activity and increased E-cadherin expression, reflecting reduced metastasis of these cells in vivo (98) .
Angiogenesis In addition to affecting the proliferation of cancer cells directly, oxytocin can stimulate proliferation and migration of endothelial cells, and can induce capillary outgrowth (106, 107) . In cancer and endometriosis this might have sinister implications. On a more positive aspect this implies that oxytocin might help in wound healing.
Dysregulation of oxytocin signalling in cancer cells
Normal oxytocinergic actions are thought to be altered in some cancers owing to dysregulated expression of both oxytocin and its receptor ( Table 3 ). The most notable example of this is in small cell lung carcinomas which display increased oxytocin and oxytocin receptor expression, implicating oxytocin as an oncogenic factor through an autocrine/ paracrine mechanism (94) . By contrast, some prostate cancer cell lines and prostate tumours display decreased oxytocin expression but increased oxytocin receptor expression, most markedly following the acquisition of androgen independence (96) . The implications of these alterations are unclear owing to the apparent heterogeneous effects of oxytocin on prostate cancer cell proliferation. In endometrial tumours, the oxytocin receptor redistributes to the cytoplasm in aggressive tumours. It is unclear how this arises but is proposed to reflect a loss of antitumorigenic action of oxytocin in these cell types (97) .
Benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is a disease in ageing males resulting primarily from overgrowth of the stroma in the periurethral and transition zones. It affects more than 50% of men over the age of 60 years (5, 108) . The aetiology of BPH is unclear, but a significant factor is thought to be an increase in the oestrogen:androgen ratio that occurs with age (109) . This stimulates prostatic secretion of oxytocin that is not subject to negative feedback regulation that is present in rodent prostates (110) . The consequences of excessive oxytocin secretion can act to direct stromal cell growth indirectly by increasing the conversion of testosterone to dihydrotestosterone (DHT). Increased conversion of testosterone to DHT is enabled as oxytocin increases the activity of 5a reductase isoforms I and II and can additionally increase the expression of 5a II isoform in the rat ventral prostate (111) . Similarly, oxytocin increases expression of 5a-reductase I and the activity of both isoforms of 5a-reductase in human prostatic epithelial cells (112) . Moreover, oxytocin can contribute directly to the increased prostatic tone by increasing contraction of prostatic fibromuscular cells (113) .
Nocioception
Oxytocin is thought to reduce the sensation of pain by intercepting pain signals at the level of the spinal cord and brain. Within the spinal cord, oxytocin triggers the release of glutamate from a distinct population of glutaminergic neurons. Glutamate excites GABAergic neurons resulting in synaptic inhibition in lamina II (114) . Within the brain, the antinociceptive effect of oxytocin is probably as a result of an interaction between oxytocin and opioid receptor signalling (115) . In rats, oxytocin administration can increase pain threshold as indicated by a reduced paw withdrawal time in response to mechanical and thermal stimulation (115) . In humans, very low doses of oxytocin are effective in reducing the sensation of a finger prick (116) .
Indeed, oxytocin signalling is dysregulated in pain conditions. In chronic back pain sufferers, oxytocin levels are reduced within the CSF and plasma, whereas in acute back pain sufferers, plasma oxytocin levels are reduced, but CSF levels are unchanged. The injection of oxytocin intrathecally eradicated or reduced pain in a large number of patients (117) . Additionally, oxytocin is reduced in people with fibromyalgia, a chronic rheumatic condition marked by point tenderness in joints (118) . The possibility of oxytocin use in pain management is the subject of current clinical trials investigating the effect of oxytocin on chronic headaches and interstitial cystitis, a chronic inflammatory condition of the bladder associated with pelvic pain (Table 1) .
Injury and inflammation
In rats, ischemia and reperfusion injuries can be ameliorated by oxytocin pretreatment in the heart, liver and kidney but different mechanisms have been assigned to each. In the heart, oxytocin administration prior to ischemia could reduce infarct size owing to a reduction in coronary blood flow, and reduced metabolic demand of the tissue as indicated by a reduction in rate of contraction (119) . In the liver, oxytocin administration prior to reperfusion prevented inflammation as indicated by reduced tumour necrosis factor (TNF) levels and neutrophil infiltration. Less tissue damage was also observed with a reduction in morphological damage, reduced plasma liver enzyme content and reduced free radical induced fibrosis (120) . Similarly, oxytocin administration prior to reperfusion in the kidney could improve inflammation, tissue histopathology and renal function. In contrast to the liver, however, this was found to be as a result of reduced lipid peroxidation and reactive oxytocin species generation (121) .
In rats, thermal skin injuries are associated with systemic effects including oxidative destruction of the gastric mucosa. Administration of oxytocin is effective at reducing both the localised and systemic injury associated with thermal injury (122) . The reduction in cortisol observed within this study is suggestive of this being due to an anxiolytic effect of oxytocin, but anti-inflammatory and antipain effects are also implicated (122) . Additionally, oxytocin can reduce atherosclerosis in ApoE -/-mice, again a result of oxytocins antiinflammatory actions (123) .
Anorgasmia and oligospermia
Oxytocin has been proposed for the treatment of anorgasmia and for improvement of sperm concentration of the ejaculate. In animals, oxytocin can increase semen volume and number of ejaculated sperm in rams (124) , induce shedding of spermatozoa from the seminiferous tubules and induce sperm movement through the reproductive tract of rats, mice and rabbits (68, 69, 125) . Furthermore, the peak of oxytocin at orgasm is highly suggestive that oxytocin contributes to ejaculation in humans (38, 72) . In a case study of a male with anorgasmia, ejaculation was restored with intracoitally administered oxytocin (126) . In the treatment of oligospermia, however, a single dose of oxytocin was ineffective in increasing sperm numbers in the ejaculate (127) .
Osteoporosis
Both male and female mice lacking either oxytocin or the oxytocin receptor display severe loss of bone mass (osteoporosis) (128) . Consistent with this, plasma oxytocin levels are significantly lower in osteoporotic postmenopausal women compared with non-osteoporotic women (129) . Such bone loss can be inhibited by administration of oxytocin in a mouse model of osteoporosis (129) . This action is modulated by the ability of oxytocin to induce osteoblast differentiation and mineralisation while inhibiting bone resorption by mature osteoclasts (128) . By contrast, oxytocin increases the formation of osteoclasts (128, 130) , and possibly transfer of calcium from mother to offspring during pregnancy (130) . Hence, oxytocin might be important for maternal bone resorption and calcium mobilisation, and subsequent skeletal remineralisation that is seen in pregnancy and lactation (130) .
Expert opinion
Oxytocin has great potential for the treatment of disorders such as autism, schizophrenia and depression. To realise this potential, a greater understanding of the dysregulation within oxytocinergic systems is needed. To date, studies have only investigated alterations to CSF and circulating levels of oxytocin, and on polymorphisms in the oxytocin receptor. No studies have been performed on humans to determine changes in oxytocin receptor density or distribution in the brain that can account for altered sensitivity to oxytocin in people with these disorders. Studies performed thus far have indicated that not all people respond to oxytocin treatment. Furthermore, studies are required to determine systemic effects of long-term oxytocin treatment before this can be considered an option. Previous data has illustrated that long-term oxytocin can affect plasma osmolality and induce psychosis which, although reversible (76) , are undesirable side effects with potentially devastating consequences. This review has identified several diseases that are potentially contraindicated for the use of oxytocin, such as some cancers and BPH, but that might benefit from oxytocin antagonist treatment. In terms of pain relief, there are some concerns that the actions of oxytocin are owing to a sedative effect rather than an actual reduction in pain (114, 117) .
Outlook
We anticipate that research into oxytocinergic systems will continue to attract wide attention, particularly in areas of social behaviour and cognition. Within the past few years, the number of diseases being investigated with oxytocin treatment has increased and is bound to increase further. Once a greater understanding of the subtleties in oxytocin signalling that are evident between cell and tissue types is achieved it is expected that some of those pathologies in which oxytocin is implicated will be targeted for treatment by oxytocin or antagonists. Indeed, clinical trials of disorders such as schizophrenia and autism are already in stage II and stage IV with no adverse effects of oxytocin being reported. It is therefore probable that oxytocin will be implemented in the treatment of these disorders, where inadequate treatment is currently available.
Highlights
• Oxytocin is a highly pleiotropic hormone.
• Oxytocin mediates social behaviour and is thus seen as a potential treatment option for disorders associated with decreased social function such as autism, depression and schizophrenia.
• Oxytocin can alleviate physical injury by reducing inflammation, nocioception and associated stress, implicating oxytocin as a potential therapy of trauma.
• Oxytocin modulates cancer cell behaviour. Mechanisms are poorly understood and are being investigated.
• Oxytocin antagonists provide potential treatments for diseases where oxytocin could have sinister actions (e.g., some cancers and BPH). 
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